Pure Encapsulations® Introduces PureHeart™ Probiotic with Exclusive Probiotic Strain
The Newest Addition to The PureHeart™ Protocol
October 24, 2013 Sudbury, MA Pure Encapsulations®, a leading manufacturer of research-based, hypo-allergenic nutritional supplements, is proud to introduce PureHeart™ Probiotic, the newest addition to The PureHeart™ Protocol: Screening + Supplements = Success™ line of nutritional supplements. PureHeart™ Probiotic offers a clinically researched probiotic strain exclusive to Pure Encapsulations.
“With the proprietary probiotic strain Lactobacillus reuteri NCIMB 30242, PureHeart™ Probiotic offers evidence-based support from a new angle in clinical cardiology,” states Kelly C. Heim, Ph.D., Nutritional Pharmacologist at Pure Encapsulations. “This exclusive formulation addresses basic aspects of lipid metabolism and vascular function.*”
Micropharma, the supplier of Lactobacillus reuteri NCIMB 30242, is a Canadian biotechnology company focused on human metabolic health through the microbiome. Leadership in cardiometabolic product innovation and research makes Pure Encapsulations the ideal partner for Micropharma to first introduce this ingredient to the healthcare practitioner market.
Lactobacillus reuteri NCIMB 30242 was developed using the Micropharma ProSelect proprietary technology platform designed to screen and select non-GMO, probiotic candidates. Studies have indicated three key functions of the strain:
- Maintenance of healthy cholesterol levels already in the normal range*
- Maintenance of healthy apolipoprotein B-100/apolipoprotein A-1 ratios already in the normal range*
- Support of healthy plasma fibrinogen levels to promote healthy blood flow*
Furthermore, research has found that this unique strain provided in PureHeart™ Probiotic may encourage healthy lipid metabolism by promoting the production of deconjugated bile acids, which play an important role in the absorption of fat from the G.I. tract.*
Special features of PureHeart™ Probiotic also include its shelf-stable formulation and acid-resistant capsules. These features allow for maintained viability without refrigeration and maximum probiotic delivery to the G.I. tract. Since the strain is grown on a dairy-free, soy-free medium, it is suitable for individuals with sensitive or restrictive diets.
For more information on PureHeart™ Probiotic, or to request a copy of The PureHeart™ Protocol: Screening + Supplements = Success™ brochure, please contact Bryanna Charbonneau at bcharbonneau@PureEncapsulations.com or visit www.PureEncapsulations.com.
About Pure Encapsulations®
A business unit of Atrium Innovations Inc. (TSX: ATB), Pure Encapsulations is committed to producing a complete line of research-based nutritional supplements. Available through health professionals, finished products are pure and hypo-allergenic to optimize the long-term health of the most sensitive patients.* Pure Encapsulations is an industry leader in quality, with an extensive raw material and finished product testing program that includes analysis for identity, potency, environmental contaminants, oxidation and more by certified third party laboratories. Pure Encapsulations is NSF-GMP registered in the U.S., GMP certified in Canada and exceeds the standards of the United States Pharmacopeia (USP) for supplement manufacturing. For additional information, please visit www.PureEncapsulations.com. For more information about Micropharma, visit www.micropharma.net.
About Atrium Innovations
Atrium Innovations Inc. (TSX: ATB) is a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based natural health products which are distributed in more than 35 countries. The Company owns healthcare practitioner and specialized retail product brands that are at the forefront of science, innovation and education. Atrium has over 1,100 employees and operates seven manufacturing facilities complying with current Good Manufacturing Practices. Additional information is available at www.atrium-innovations.com.